8-K: X4 Pharma Secures $85M in Upsized Private Placement

X4 Pharmaceuticals successfully closed an upsized $85 million private placement to fund clinical trials and commercialization efforts.

Summary

• X4 Pharmaceuticals, Inc. (XFOR) closed an upsized private placement on August 13, 2025, raising aggregate gross proceeds of $85,000,000.
• The financing included the sale of 11,040,776 shares of common stock and pre-funded warrants to purchase 48,852,772 shares of common stock.
• The purchase price for common stock was $1.42 per share, and for pre-funded warrants, it was $1.419 per warrant.
• Pre-funded warrants have an exercise price of $0.001 per share, are exercisable at any time, and do not expire.
• Following the closing, the fully-diluted shares outstanding are approximately 87.2 million.
• The offering was led by Coastlands Capital, with support from existing investors including Empery Asset Management, LP, Bain Capital Life Sciences, New Enterprise Associates (NEA), BVF Partners LP, Deep Track Capital, Kalehua Capital, Nantahala Capital, Stonepine Capital Management, and Trails Edge Capital Partners.
• The securities were sold in a private offering, exempt from public registration, with investors confirming their accredited investor status.

Sentiment

Score: 8

Explanation: The successful and upsized private placement, securing significant capital for critical clinical development and commercialization, indicates strong investor confidence and provides a solid financial runway for the company's strategic objectives. This is a highly positive development for a biotech firm.

Positives

• Successfully completed an upsized private placement, raising $85 million, exceeding the originally announced $60 million.
• Strong investor support from both new and existing leading life science investors, including Coastlands Capital, Empery Asset Management, Bain Capital Life Sciences, and New Enterprise Associates.
• Proceeds are earmarked for critical development activities, specifically the Phase 3 clinical trial of mavorixafor (4WARD study) for chronic neutropenia and commercialization of WHIM.

Negatives

• The capital raise results in dilution, with fully-diluted shares outstanding increasing to approximately 87.2 million.

Risks

• Future financial performance and position may not improve, potentially hindering business strategy and operations.
• Existing cash resources and runway may not be sufficient, leading to a need for additional financing sooner than anticipated or unexpected liquidity constraints.
• Internal and external costs for ongoing and planned activities may be higher than expected, potentially accelerating cash burn or requiring changes to plans.
• Expected availability, content, and timing of clinical data from ongoing clinical trials of mavorixafor may be delayed or unavailable.
• Clinical trials and studies may be delayed and may not yield satisfactory outcomes, and earlier trial results may not be predictive of later trials.
• The design and enrollment rate for clinical trials, including the Phase 3 clinical trial for mavorixafor in chronic neutropenic disorders, may not enable successful completion.
• The commercial opportunity for mavorixafor in chronic neutropenic disorders may be smaller than anticipated.
• Inability to obtain and maintain regulatory approvals.
• Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development.
• Potential for adverse safety effects from the testing or use of products and product candidates.
• Need to align with collaborators may hamper or delay development and commercialization efforts or increase costs.
• Business may be adversely affected and costs may increase if any key collaborators fail to perform obligations or terminate collaborations.
• Challenges in advancing and commercializing mavorixafor for chronic neutropenia or optimizing U.S. promotion of XOLREMDI (mavorixafor) for WHIM.

Future Outlook

The company expects to use the net proceeds from the financing to support the full enrollment of its ongoing Phase 3 clinical trial of mavorixafor (the 4WARD study) for chronic neutropenia, for general corporate purposes, and for the commercialization of WHIM. The company has also agreed to file a registration statement with the SEC to register the resale of the shares of common stock and the shares underlying the pre-funded warrants.

Management Comments

• The company is driven to improve the lives of people with rare diseases of the immune system.
• The company is leveraging expertise in CXCR4 and immune system biology.
• The company has successfully developed mavorixafor, an orally available CXCR4 antagonist, currently marketed in the U.S. as XOLREMDI in its first indication.
• The company is evaluating additional uses of mavorixafor and conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders.

Industry Context

This capital raise by X4 Pharmaceuticals is consistent with trends in the biotechnology and rare disease sectors, where significant capital is often required to fund late-stage clinical trials and commercialization efforts for novel therapies. The participation of specialized life science investors indicates continued confidence in the potential of mavorixafor and the company's pipeline, despite the inherent risks of drug development.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential dilution from the issuance of new shares and warrants, but also benefit from strengthened financial position and funding for key development programs, which could drive future value.
• **Employees:** Enhanced job security and stability due to improved financial health and continued funding for research and development.
• **Customers/Patients:** Increased likelihood of mavorixafor advancing through clinical trials and potentially gaining additional approvals, leading to new treatment options for chronic neutropenic disorders.
• **Creditors:** Improved financial stability and liquidity, potentially reducing credit risk.

Next Steps

• File a registration statement with the SEC to register the resale of the shares of common stock and the shares underlying the pre-funded warrants.
• Continue efforts to achieve full enrollment of the ongoing Phase 3 clinical trial of mavorixafor (the 4WARD study) for chronic neutropenia.
• Continue commercialization efforts for WHIM.

Key Dates

Recommendation

The successful and upsized $85 million private placement significantly strengthens X4 Pharmaceuticals' financial position, providing crucial capital for the advancement of its pivotal Phase 3 clinical trial for mavorixafor in chronic neutropenia and the commercialization of WHIM. This substantial funding, coupled with strong backing from reputable life science investors, de-risks the company's near-term operational funding needs and signals strong market confidence in its pipeline and strategic direction. While dilution is a factor, the capital infusion for key value-driving assets outweighs this, positioning the company for potential future growth and regulatory milestones. This development is a strong positive catalyst for the stock.

Keywords

X4 Pharmaceuticals, XFOR, Private Placement, Capital Raise, Pre-funded Warrants, Common Stock, Mavorixafor, WHIM, Chronic Neutropenia, Phase 3 Clinical Trial, 4WARD Study, Biotechnology, Rare Diseases, Immunology, SEC Filing, Investment